|
 |
|
|||||||
|
|||||||||
Copyright ©ERS Journals Ltd 2002
Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium
1 Respiratory Division, Academic Hospital University of Brussels (AZ VUB), Brussels, Belgium. 2 Dept of Respiratory Diseases, Atrium Medisch Centrum, Heerlen, the Netherlands. 3 Dept of Respiratory Diseases, St Streekziekenhuis Midden Twente, Hengelo, the Netherlands. 4 Dept of Respiratory Diseases, Ignatius and Barouie Hospitals, Breda, the Netherlands. 5 Boehringer Ingelheim, Ridgefield, CT, USA. 6 Boehringer Ingelheim, Alkmaar, the Netherlands
CORRESPONDENCE: W. Vincken, Respiratory Division, AZ VUB (Academic Hospital University of Brussels), 101 Laarbeeklaan, 1090, Brussels, Belgium. Fax: 32 2 4776019. E-mail: Walter.vincken@az.vub.ac.be
Keywords: chronic obstructive pulmonary disease, dyspnoea, exacerbations, ipratropium, quality of life, tiotropium.
Received: June 7, 2001
Accepted November 7, 2001
 |
Abstract |
|---|
 TOP Abstract MethodsResultsDiscussionAcknowledgementsReferences |
|---|
Tiotropium, a novel once-daily inhaled anticholinergic, has been shown to improve lung function over a 24-h period. In order to extend these findings, health-outcomes were evaluated over 1 yr in chronic obstructive pulmonary disease (COPD) patients.
Spirometric results, peak expiratory flow rate (PEFR), salbutamol use and effects on dyspnoea, health-related quality of life and COPD exacerbations were assessed in two identical 1-yr randomized double-blind double-dummy studies of tiotropium 18µg once daily (n=356) compared with ipratropium 40µg q.i.d. (n=179).
Screening forced expiratory volume in one second (FEV1) were 1.25±0.43 L (41.9±12.7% of the predicted value) (tiotropium) and 1.18±0.37 L (39.4±10.7% pred) (ipratropium). Trough FEV1 at 1 yr improved by 0.12±0.01 L with tiotropium and declined by 0.03±0.02 L with ipratropium (p<0.001). Significant improvement in PEFR, salbutamol use, Transition Dyspnea Index focal score, and the St George's Respiratory Questionnaire total and impact scores were seen with tiotropium (p<0.01). Tiotropium reduced the number of exacerbations (by 24%, p<0.01), and increased time to first exacerbation (p<0.01) and time to first hospitalization for a COPD exacerbation (p<0.05) compared with ipratropium. Apart from an increased incidence of dry mouth in the tiotropium group, adverse events were similar between treatments.
Tiotropium was effective in improving dyspnoea, exacerbations, health-related quality of life and lung function in patients with chronic obstructive pulmonary disease, and exceeds the benefits seen with ipratropium. The data support the use of tiotropium once-daily as first-line maintenance treatment in patients with chronic obstructive pulmonary disease.
Inhaled anticholinergics such as ipratropium have been recommended as first-line maintenance bronchodilator medication for chronic obstructive pulmonary disease (COPD) patients with regular symptoms 1, 2. Anticholinergic therapy is beneficial due to the increased cholinergic airway tone in COPD mediated through the vagus nerve 3.
The 6-h duration of action of ipratropium led to the search for and clinical development of tiotropium, a novel once-daily inhaled anticholinergic bronchodilator. The sustained bronchodilation caused by tiotropium is explained by its prolonged M3 muscarinic receptor antagonism 4, 5. van Noord et al. 6 recently published a study of 288 patients with COPD, documenting significant improvements in spirometric values over 3 months in patients receiving tiotropium 18 µg once daily compared with ipratropium 40 µg q.i.d. These patients continued into a 1-yr randomized double-blind trial. The present report describes the combined results of this study and a second large multicentre 1-yr trial comparing the effect of tiotropium 18 µg once daily with that of ipratropium 40 µg q.i.d. on lung function, dyspnoea, exacerbation rate and health-related quality of life (HRQOL) in patients with COPD.
|
Methods |
|---|
|
TOPAbstractMethodsResultsDiscussionAcknowledgementsReferences |
|---|
Study design
The two 1-yr studies incorporated a randomized double-blind double-dummy parallel group design. Randomization to tiotropium 18 µg once daily in the morning or ipratropium 40 µg q.i.d. occurred on a 2:1 ratio, such that twice as many patients were exposed to tiotropium. Tiotropium was supplied as a dry powder capsule and inhaled through the HandiHaler® device (Boehringer Ingelheim, Ingelheim am Rhein, Germany). Ipratropium was administered using a metered-dose inhaler (MDI). Patients were permitted salbutamol MDIs (100 µg per actuation) as needed for acute symptom relief. Other ß-agonists (long and short acting) and inhaled anticholinergic medications (other than study drugs) were not permitted. Concomitant use of theophyllines, inhaled steroids and oral steroids (at a dose of
![{els]](/math/els.gif)
10 mg·day–1 prednisolone or equivalent) was allowed if the dosage was stable for 
6 weeks before screening. The studies were conducted at 29 sites in the Netherlands and Belgium. The protocol was approved by independent ethics committees, and informed consent was obtained from all patients.
Patients
Patients were required to have a clinical diagnosis of COPD, a forced expiratory volume in one second (FEV1) of 65% of the predicted normal value 7 and 70% of forced vital capacity (FVC). Patients were also required to be 40 yrs of age and have a smoking history of 10 pack-yrs. Patients with a history of asthma, allergic rhinitis or atopy or an elevated total blood eosinophil count were excluded, as were patients requiring regular supplemental oxygen and those with a recent upper respiratory tract infection or a significant disease other than COPD.
Study protocol
Patients were randomized following screening and a 2-week baseline period. Spirometry was conducted in the outpatient clinic at screening and on day 1 (randomization) as well as after 1, 7, 13, 26, 39 and 52 weeks of therapy. Testing was performed 1 h before drug administration, immediately before drug administration, and at 30, 60, 120 and 180 min after dosing (and at 240, 300 and 360 min on day 1 and at 1, 7 and 13 weeks). The highest FEV1 and FVC from three technically adequate measurements were retained. Peak expiratory flow rates (PEFRs) were self-measured by patients twice daily (upon arising and at bedtime) using a Mini-Wright Peak Flow Meter (Clement Clarke International, Harlow, UK). Patients were requested to record the best of three efforts. Patients also recorded the number of puffs of "as needed" salbutamol used.
Dyspnoea was evaluated using the Baseline Dyspnea Index (BDI) and the Transition Dyspnea Index (TDI) 8. HRQOL was determined using the St George's Respiratory Questionnaire (SGRQ) 9 and the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) 10.
Safety assessments included a complete blood count, biochemistry, urinalysis and electrocardiogram on entry and upon completion of the study. An exacerbation, identified through monitoring of adverse events, was defined as a complex of respiratory symptoms (i.e. new onset or worsening of more than one symptom such as cough, sputum, dyspnoea or wheeze) lasting 3 days.
Analysis
Analysis of covariance with baseline as covariate was used, with terms for treatment and study centre. Baseline FEV1 and FVC were set as the mean of the two measurements obtained on day 1 prior to the first dose of study medication. Trough FEV1 and FVC were calculated as the mean of the two predose measurements on subsequent clinic visits (i.e. 
23–24 h after the preceding tiotropium dose or 8–9 h after the preceding ipratropium dose). The trough FEV1 response was defined as trough FEV1 minus baseline value. For PEFR and salbutamol use, the mean of observations obtained during the week before the treatment period were used as baseline data. For TDI focal score, a difference of 1 unit was considered clinically meaningful. For the SGRQ impact and total scores, a difference of 4 units was considered clinically meaningful. The proportions of patients with at least one COPD exacerbation or hospitalization due to an exacerbation over the 1-yr study period were compared using logistic regression adjusted for extent of exposure. For comparison of the number of COPD exacerbations, exacerbation days, hospitalizations due to exacerbation and hospitalization days across treatment groups, the Wilcoxon-Mann-Whitney test was used. The two treatment groups were also compared in terms of time to first exacerbation and time to first hospitalization due to an exacerbation using the log-rank test. Means were adjusted for baseline in the presentation of serial data over time. Statistical significance was considered at p<0.05.
The intention-to-treat (ITT) principle was used to include as many randomized patients as possible in the analyses. This consisted of all patients for whom baseline data and data after multiple administration of study medication were available. In keeping with the ITT principle, patients were not excluded from any analyses due to protocol violations. Since the number of these was small, there was little or no impact on the results. For patients who discontinued the study early due to worsening of COPD, missing efficacy data were estimated using the least favourable data observed prior to discontinuation. Missing data for patients who missed a visit not related to worsening of COPD were estimated using their last observed data. In order to include the same patients at each time point in the spirometry summaries, missing values were estimated using other values recorded for the patient on that test day. Linear interpolation between the two adjacent measurements was used to estimate middle missing spirometry measurements. For values at the ends of the profiles that were missing because rescue medication was taken, the minimum observed FEV1 on that test day was used as the estimate. Patients who could not complete all visits due to drug expiration were requested to discontinue the study drug at the 9-month visit but were considered complete patients. Homogeneity of effect was measured for the primary endpoint by including an analysis with treatment by centre interaction and examining the effects for the various centres.
A sample size of 60 patients per group was calculated as adequate to detect a difference of 0.13 L in trough FEV1 based on an sd of 0.215 L. To ensure adequate safety exposure, a sample size of 240 patients (160 tiotropium and 80 ipratropium) was selected for each trial.
|
Results |
|---|
|
TOPAbstractMethodsResultsDiscussionAcknowledgementsReferences |
|---|
Patient demographics
A total of 535 patients were randomized, 356 receiving tiotropium and 179 receiving ipratropium. More patients in the tiotropium group completed the trials compared to the ipratropium group (84.8 versus 78.8%), predominantly due to fewer adverse events, including COPD exacerbations (table 1
); however, there was no significant difference in the proportion of patients who completed the trial (p=0.08, Fisher's exact test). Thirteen per cent of patients in each treatment group (tiotropium, n=47; ipratropium, n=24) were discontinued due to drug expiration. Although resupply of the study drug was originally planned, it was deemed unnecessary as the target sample size had been attained due to the lower-than-expected frequency of early withdrawals over the year. Demographic data and respiratory medication use at screening were comparable across treatment groups (table 2). The screening FEV1 was 1.25±0.43 L (41.9% pred) and 1.18±0.37 L (39.4% pred) for the tiotropium and ipratropium groups respectively (mean±sd).
|
|
Spirometry
Patients showed a significant bronchodilator response within 30 min after the first dose of tiotropium (fig. 1
). By the end of the first week (day 8), the mean trough FEV1 (24 h after treatment with tiotropium and prior to the morning ipratropium dose) was 140 mL above baseline for patients in the tiotropium group (a 12% increase) compared with 20 mL for those in the ipratropium group. Tiotropium was superior to ipratropium (p<0.05) at all time points on all test days except for the first 2 h following the first dose and up to 1 h after the dose 1 week later. At the end of 1 yr, trough FEV1 was 120 mL above the day 1 baseline for patients receiving tiotropium, and had declined by 30 mL for those receiving ipratropium (difference of 150 mL between groups, p<0.001 at all time points) (fig. 2). Further, this trough FEV1 was 20 mL lower than the trough FEV1 on day 8 (after pharmacodynamic steady state) for the tiotropium group, whereas for ipratropium this difference was 50 mL.
|
) or ipratropium (
) at baseline (day 1, –––– ) and after 8 (- - - - -) and 364 (– – –) days.
|
) in trough forced expiratory volume in one second (FEV1) following inhalation of tiotropium (
) and throughout the 1-yr trials (p<0.001 at all time points).The FVC results paralleled the FEV1 results. By the end of the first week, the mean trough FVC response (
24 h after treatment with tiotropium and prior to the morning ipratropium dose) was 320 mL for patients in the tiotropium group and 80 mL for the ipratropium group. The difference between the tiotropium and ipratropium response was significant (p<0.05) at trough and at all time points at 2 h and beyond on all test days. At the end of 1 yr, the trough FVC was 320 mL above the day 1 baseline for patients receiving tiotropium and 110 mL for those receiving ipratropium (mean difference of 210 mL between groups). Spirometry results were consistent across centres.
Peak expiratory flow rate
Baseline morning and evening PEFRs for the tiotropium group (253±4.1 and 262±4.1 L·min–1, respectively) were comparable to those for the ipratropium group (244±5.9 and 254±6.0 L·min–1, respectively). Throughout the 1-yr treatment period, morning and evening PEFR improved significantly more in the tiotropium group than in the ipratropium group (p<0.01 at all weekly intervals). The difference between the two groups ranged 10–18 L·min–1 in the morning and 9–18 L·min–1 in the evening.
Dyspnoea
The BDI focal scores (mean±sem) for the tiotropium group (7.13±0.14) and ipratropium group (7.41±0.19) were comparable. Tiotropium significantly improved all three components of the TDI, as well as the focal score, on all test days compared to ipratropium (p<0.05). The differences in TDI focal score between the tiotropium and ipratropium groups at 9 and 12 months were 0.97±0.25 and 0.90±0.26, respectively (fig. 3a, table 3). The proportion of patients who achieved a clinically meaningful difference in TDI focal score (improvement of 1 unit) at 1 yr was significantly greater in the tiotropium group (31%) than in the ipratropium group (18%, p=0.004) (fig. 3b). Based on the results of the study, the number needed to treat (NNT) to obtain at least a 1-unit improvement in the TDI focal score over a population that would otherwise receive regular ipratropium would be eight.
|
) and ipratropium (
|
Health-related quality of life
At baseline, the SGRQ total scores (mean±sem) for tiotropium and ipratropium were similar (45.4±0.92 and 43.2±1.36, respectively). During the 1-yr treatment period, the SGRQ total score decreased (improved) in both groups, but gradually returned towards baseline in the ipratropium group (fig. 4a
). Improvements were maintained over the year in the tiotropium group, and were superior to ipratropium (difference of 3.30±1.13 on day 364, p<0.05) (table 3
). At 1 yr, the mean change from baseline in SGRQ total score was –3.74 for tiotropium and –0.44 for ipratropium. From day 92 to the end of the study, the improvement in the impacts score was significantly greater with tiotropium than with ipratropium (p=0.004). The difference between the two groups in the impacts score was 4.28±1.32 on day 364 (p=0.001). For both the symptoms and activities domains, similar improvements were seen in both groups (table 3).
|
More patients in the tiotropium group than in the ipratropium group achieved the clinically meaningful improvement of 4 units in the SGRQ total score after 9 and 12 months (52 versus 35% respectively, at 1 yr, p=0.001) (fig. 4b
). The NNT to obtain at least a 4-unit improvement in SGRQ total score over a population that would otherwise receive regular ipratropium would be six.
SF-36 baseline data were comparable across the two treatment groups. Tiotropium was more effective than ipratropium in all physical domains (higher scores); however, the differences between the treatment groups were only significant in physical health summary on the last 2 test days (days 273 and 364). In the mental health domains, the differences in scores between the treatment groups were less consistent and were generally not significant (table 3).
Exacerbations of chronic obstructive pulmonary disease
The proportion of patients experiencing one or more exacerbations during the 1-yr treatment period was significantly lower in the tiotropium group than in the ipratropium group (35 versus 46%, respectively, p=0.014). The number of exacerbations·patient–1·yr–1 was 24% lower in the tiotropium group (0.73 versus 0.96, p=0.006). In addition, the number of exacerbation days·patient–1·yr–1 was 39% lower in the tiotropium group (10.8 versus 17.7, p=0.002). The time to first exacerbation was significantly longer in patients receiving tiotropium (p=0.008) (fig. 5a).
|
Similar findings were observed for hospitalizations due to COPD exacerbations during the 1-yr treatment period. The proportion of patients hospitalized for a COPD exacerbation were 7.3 and 11.7% in the tiotropium and ipratropium groups, respectively (p=0.11). The number of hospitalizations·patient–1·yr–1 for a COPD exacerbation was 38% lower in the tiotropium group (0.10 versus 0.16, p=0.08), and the number of hospitalization days·patient–1·yr–1 was 33% lower in patients receiving tiotropium (1.42 versus 2.13, p=0.09). Furthermore, the time to first hospitalization due to a COPD exacerbation was significantly longer in the tiotropium group (p=0.048) (fig. 5b
).
Use of as needed (rescue) salbutamol
On average, patients receiving tiotropium self-administered approximately four fewer inhalations of salbutamol·week–1 compared to patients receiving ipratropium (p<0.05 for 40 of the 52 weeks).
Safety
The proportions of patients experiencing adverse events leading to discontinuation were 10.1 and 12.8% in the tiotropium and ipratropium groups, respectively. These differences, although not significant (p=0.089), were predominantly the result of fewer respiratory events. There were no differences in the proportion of patients who died during the trial (tiotropium, 2.5% (n=9); ipratropium, 1.7% (n=3)). The only adverse event consistently reported as possibly related to tiotropium was dry mouth, which was noted more frequently with tiotropium (12.1%) than with ipratropium (6.1%) (p=0.03, Fisher's exact test). Dry mouth was generally reported as mild, resolved during treatment in the majority of patients and did not lead to discontinuation in any patient receiving tiotropium. No laboratory or electrocardiographic abnormalities were observed that could be attributed to tiotropium.
|
Discussion |
|---|
|
TOPAbstractMethodsResultsDiscussionAcknowledgementsReferences |
|---|
The present trials provide long-term information on the bronchodilatory benefits of tiotropium, a novel once-daily inhaled anticholinergic bronchodilator, compared to ipratropium, a medication widely used in the treatment of COPD. The results indicate that tiotropium provides sustained improvements in lung function, dyspnoea, exacerbations and HRQOL over 24 h throughout 1 yr of treatment. The results support a previous single-dose study in patients with COPD, which showed that once-daily dosing with tiotropium results in significant spirometric changes 24 h later 11. A placebo-controlled 4-week dose-ranging study supported the 24-h effects on spirometry with once-daily tiotropium 12.
Treatment with ipratropium leads to significant bronchodilation, with recent data suggesting other tangible benefits such as improvement in dyspnoea and hyperinflation and decreased exacerbations of COPD 13–17. However, although effective, the recommended four times daily dosing leads to diminished compliance 18 and possibly suboptimal benefits from bronchodilator therapy. Tiotropium has the advantage of once-daily dosing, enhancing convenience and eliminating the need to carry maintenance medication whilst away from home. More importantly, in the present study, the prolonged bronchodilation achieved with tiotropium provides superior benefits in pulmonary function (FEV1 and FVC), dyspnoea, exacerbations and HRQOL compared to ipratropium.
In addition to the 24-h bronchodilation, it was interesting to note that the loss of lung function (based on predose morning FEV1) from day 8 (pharmacodynamic steady state for tiotropium) to 1 yr was only 20 mL for tiotropium compared with a loss of 50 mL for ipratropium, suggesting a slowing of the rate of decline in lung function over time. Definitive conclusions would require a longer study period.
Dyspnoea is the most frequent complaint of patients with COPD requiring medical intervention and is the most prominent symptom limiting the activity of daily living. The TDI is a validated questionnaire that quantifies and distinguishes changes in breathlessness over time in COPD patients 8. In a 12-week study of 411 patients with symptomatic COPD (mean FEV1 40% pred), ipratropium improved TDI scores relative to placebo at the end of the trial, whereas salmeterol was of no significant benefit 17. The present study demonstrates that tiotropium was superior to ipratropium in improving dyspnoea at all time points over 1 yr, as assessed by the difference in mean TDI scores, and by the proportion of subjects who demonstrated a clinically meaningful improvement (1 unit change in focal score). Reduction in dyspnoea due to bronchodilators such as tiotropium is probably secondary to improvements in both airflow limitation and hyperinflation 19.
Assessment of HRQOL can be accomplished using both generic and disease-specific quality-of-life questionnaires. Disease-specific questionnaires for COPD have shown a weak correlation with lung function, but provide additional useful information over and above standard spirometric indices 9. There are conflicting reports as to the effectiveness of salmeterol in improving HRQOL. Jones and Bosh 20 noted an improvement in SGRQ scores of >4 units over placebo with salmeterol 50 µg b.i.d. but not 100 µg b.i.d. Rutten-van Molken et al. 21, in a study of health status questionnaires, did not notice any differences between salmeterol and placebo, although the full data have yet to be published. The present study suggests that questionnaire-based assessments of HRQOL can distinguish effects between bronchodilators. The benefits seen with tiotropium compared to ipratropium were noted with both the generic (SF-36) and disease-specific (SGRQ) questionnaires. Based on the present study, tiotropium appears to improve and maintain HRQOL, whereas regular ipratropium is not associated with long-term improvements.
As COPD progresses, the increased frequency and severity of exacerbations become notable 22. Hospitalizations due to exacerbations of COPD, particularly when admission to an intensive care unit is required, are predictive of an earlier mortality from COPD 23, 24. In addition, increased exacerbation frequency has been associated with worsening quality of life 25.
A medical intervention that prevents exacerbations rather than treating established events would be desirable. The Inhaled Steroids in Obstructive Lung Disease (ISOLDE) study suggested that inhaled steroids might be effective in reducing exacerbations 26. However, limited data exist demonstrating the effectiveness of bronchodilators in preventing exacerbations 16. In the 12-week trial comparing salmeterol to ipratropium and placebo reported by Rennard et al. 27, there were no differences in the percentages of patients who experienced one or more COPD exacerbations. More patients experienced exacerbations in the first week in the placebo group compared to either the salmeterol or ipratropium groups. In the present study, tiotropium, compared to ipratropium, not only prolonged the time to first exacerbation but also reduced the frequency of exacerbations and the number of exacerbation days. Further, the first hospitalization due to exacerbation was delayed and, although not statistically significant, there was also a trend towards reduced hospitalizations and days in hospital due to a COPD exacerbation.
The association of treatment with the long-acting bronchodilator tiotropium and reduction in exacerbations raises the interesting question of mechanistic explanations. One possibility is that the severity of symptoms, induced by triggers such as viral infections, is reduced through sustained bronchodilation, such that the patient does not require medical attention. A shift in severity of symptoms may translate into an outpatient visit and therapy at home rather than an urgent visit to an accident and emergency department with hospitalization. Given the enormous impact of exacerbations on the patient, and on the healthcare system, tiotropium has the potential to affect broader issues beyond symptomatic improvement.
New pharmacological entities should undergo comparative clinical trials against the best available options in studies of reasonable duration in order to appropriately position medications in treatment algorithms. In this regard, tiotropium has been compared with the presently recommended first-line therapy, ipratropium, over 1 yr and shows improved benefits in addition to a considerably more convenient dosing regimen.
Decisions in the management of chronic obstructive pulmonary disease require consideration of multiple outcome measures. Although spirometry remains foundational in diagnosis and demonstration of efficacy, symptoms, quality of life and prevention of exacerbations are of more concern to the patient and their family. In the present study, tiotropium showed consistently greater efficacy across all of the aforementioned outcome measures compared to ipratropium. Given the comparative data, once-daily administration of tiotropium should be considered as first-line maintenance treatment in patients with chronic obstructive pulmonary disease.
|
Acknowledgements |
|---|
|
TOPAbstractMethodsResultsDiscussionAcknowledgementsReferences |
|---|
Members of the Dutch/Belgian Tiotropium Study Group: Th.A. Bantje, Breda; J.M.M. van de Bosch, Nieuwegein; M.C.M. Bunnik, Boxmeer; J.P.H.M. Creemers, Hengelo; W.H. Dalinghaus, Amersfoort; M.E. Eland, Dordrecht; W.B.M. Evers, Sneek; S.J.M. Gans, Harderwijk; H.Ch. Gooszen, Eindhoven; A.P.M. Greefhorst, Hengelo; A.J. van Harreveld, Apeldoorn; J.H.L.M. van Kasteren, Geldrop; A.F. Kuipers, Zwolle; J.A. van Noord, Heerlen; G.D. Nossent, Groningen; B.J.M. Pannekoek, Delft; H.R. Pasma, Leeuwarden; A. Peters, Blaricum; W.R. Pieters, Helmond; P.E. Postmus, Amsterdam; A.J.M. Schreurs, Amsterdam; H.E.J. Sinninghe Damsté, Almelo; A.P. Sips, Utrecht; P.I. van Spiegel, Amsterdam; J. Westbroek, Heerenveen, (the Netherlands); J.L. Aumann, Hasselt; E. Janssens, Lanaken; R. Pauwels, Ghent; M. Radermecker, Liège; H. Slabbynck, Antwerp; I. Stappaerts, Antwerp; J. Verhaert, Lanaken; P. Vermeire, Antwerp; W. Vincken, Brussels (Belgium).
|
References |
|---|
|
TOPAbstractMethodsResultsDiscussionAcknowledgementsReferences |
|---|
- Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 1995;8:1398–1420.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
- American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med 1995;152:S77–S120.
- Gross NJ, Skorodin MS. Role of the parasympathetic system in airway obstruction due to emphysema. N Engl J Med 1984;311:421–425.[Abstract]
- Barnes PJ, Belvisi MG, Mak JCW, Haddad E, O'Connor B. Tiotropium bromide (Ba 679 Br), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease. Life Sci 1995;56:853–859.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
- Disse B, Speck GA, Rominger KL, Witek TJ, Hammer R. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 1999;64:457–464.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
- van Noord JA, Bantje ThA, Eland ME, Korducki L, Cornelissen PJG. A randomised controlled comparison of tiotropium and ipratropium in the treatment of COPD. Thorax 2000;55:289–294.
[Abstract/Free Full Text] - Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault J-C. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Eur Respir J 1993;6:Suppl. 165–40.[Medline] [Order article via Infotrieve]
- Mahler DA, Weinber DH, Wells CK, Feinstein AR. The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984;85:751–758.
[Abstract/Free Full Text] - Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. Am Rev Respir Dis 1992;145:1321–1327.[Web of Science][Medline] [Order article via Infotrieve]
- Ware JE, Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36). Med Care 1992;30:473–483.[Web of Science][Medline] [Order article via Infotrieve]
- Maesen F, Smeets J, Sledsens T, Wald F, Cornelissen P. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Eur Respir J 1995;8:1506–1513.[Abstract]
- Littner MR, Ilowite JS, Tashkin DP, et al. Long-acting bronchodilation with once daily dosing of tiotropium (SpirivaTM) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1136–1142.
[Abstract/Free Full Text] - Karpel JP. Bronchodilator responses to anticholinergic and ß-adrenergic agents in acute and stable COPD. Chest 1991;99:871–876.
[Abstract/Free Full Text] - LeDoux EJ, Morris JF, Temple WP, Duncan C. Standard and double dose ipratropium bromide and combined ipratropium bromide and inhaled metaproterenol in COPD. Chest 1989;95:1013–1016.
[Abstract/Free Full Text] - O'Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:542–549.
[Abstract/Free Full Text] - Friedman M, Serby CW, Menjoge SS, Wilson JD, Hilleman DE, Witek TJ Jr. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 1999;115:635–641.
[Abstract/Free Full Text] - Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999;115:957–965.
[Abstract/Free Full Text] - Rand CS, Nides M, Cowles MK, Wise RA, Connett J. Long-term metered-dose inhaler adherence in a clinical trial. The Lung Health Study Research Group. Am J Respir Crit Care Med 1995;152:580–588.[Abstract]
- Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996;153:967–975.[Abstract]
- Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997;155:1283–1289.[Abstract]
- Rutten-van Molken M, Roos B, Van Noord JA. An empirical comparison of the St George's Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial setting. Thorax 1999;54:995–1003.
[Abstract/Free Full Text] - Greenberg SB, Allen M, Wilson J, Atmar RL. Respiratory viral infections in adults with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;162:167–173.
[Abstract/Free Full Text] - Keistinen T, Tuuponen T, Kivela SL. Survival experience of the population needing hospital treatment for asthma or COPD at age 50–54 years. Respir Med 1998;92:568–572.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
- Seneff MG, Wagner DP, Wagner RP, Zimmerman JE, Knaus WA. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA 1995;274:1852–1857.
[Abstract/Free Full Text] - Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418–1422.[Web of Science][Medline] [Order article via Infotrieve]
- Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297–1303.
[Abstract/Free Full Text] - Rennard SI, Anderson W, ZuWallack R, et al. Use of a long-acting inhaled ß2-adrenergic agonist, salmeterol xinfoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1087–1092.
[Abstract/Free Full Text]
This article has been cited by other articles:
|
|
 |
|
  L. Davies and P. M. A. Calverley The evidence for the use of oral mucolytic agents in chronic obstructive pulmonary disease (COPD) Br. Med. Bull., December 22, 2009; (2009) ldp050v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gavalda, M. Miralpeix, I. Ramos, R. Otal, C. Carreno, M. Vinals, T. Domenech, C. Carcasona, B. Reyes, D. Vilella, et al. Characterization of Aclidinium Bromide, a Novel Inhaled Muscarinic Antagonist, with Long Duration of Action and a Favorable Pharmacological Profile J. Pharmacol. Exp. Ther., November 1, 2009; 331(2): 740 - 751. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Casarosa, T. Bouyssou, S. Germeyer, A. Schnapp, F. Gantner, and M. Pieper Preclinical Evaluation of Long-Acting Muscarinic Antagonists: Comparison of Tiotropium and Investigational Drugs J. Pharmacol. Exp. Ther., August 1, 2009; 330(2): 660 - 668. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Anzueto and M. Miravitlles Efficacy of tiotropium in the prevention of exacerbations of COPD Therapeutic Advances in Respiratory Disease, June 1, 2009; 3(3): 103 - 111. [Abstract] [PDF]
|
|
|
|
 |
|
 A. M Chen, S. G Bollmeier, and P. M Finnegan Long-Acting Bronchodilator Therapy for the Treatment of Chronic Obstructive Pulmonary Disease Ann. Pharmacother., December 1, 2008; 42(12): 1832 - 1842. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Najafzadeh, C A Marra, M Sadatsafavi, S D Aaron, S D Sullivan, K L Vandemheen, P W Jones, and J M Fitzgerald Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD Thorax, November 1, 2008; 63(11): 962 - 967. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. J. Gross Chronic Obstructive Pulmonary Disease: An Evidence-Based Approach to Treatment With a Focus on Anticholinergic Bronchodilation Mayo Clin. Proc., November 1, 2008; 83(11): 1241 - 1250. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Tashkin, B. Celli, S. Senn, D. Burkhart, S. Kesten, S. Menjoge, M. Decramer, and the UPLIFT Study Investigators A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease N. Engl. J. Med., October 9, 2008; 359(15): 1543 - 1554. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Haag, S. Matthiesen, U. R. Juergens, and K. Racke Muscarinic receptors mediate stimulation of collagen synthesis in human lung fibroblasts Eur. Respir. J., September 1, 2008; 32(3): 555 - 562. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. F. Rabe, W. Timmer, A. Sagkriotis, and K. Viel Comparison of a Combination of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Moderate COPD Chest, August 1, 2008; 134(2): 255 - 262. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. R. Celli Update on the Management of COPD Chest, June 1, 2008; 133(6): 1451 - 1462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. T. Diaz, A. S. Bruns, M. E. Ezzie, N. Marchetti, and B. M. Thomashow Optimizing Bronchodilator Therapy in Emphysema Proceedings of the ATS, May 1, 2008; 5(4): 501 - 505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Suissa, P. Ernst, K. L. Vandemheen, and S. D. Aaron Methodological issues in therapeutic trials of COPD Eur. Respir. J., May 1, 2008; 31(5): 927 - 933. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. E. Lower, S. Harman, and R. P. Baughman Double-Blind, Randomized Trial of Dexmethylphenidate Hydrochloride for the Treatment of Sarcoidosis-Associated Fatigue Chest, May 1, 2008; 133(5): 1189 - 1195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cazzola, W. MacNee, F. J. Martinez, K. F. Rabe, L. G. Franciosi, P. J. Barnes, V. Brusasco, P. S. Burge, P. M. A. Calverley, B. R. Celli, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers Eur. Respir. J., February 1, 2008; 31(2): 416 - 469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S D Aaron, D Fergusson, G B Marks, S Suissa, K L Vandemheen, S Doucette, F Maltais, J F Bourbeau, R S Goldstein, M Balter, et al. Counting, analysing and reporting exacerbations of COPD in randomised controlled trials Thorax, February 1, 2008; 63(2): 122 - 128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Vijayasaratha and R. A. Stockley Reported and Unreported Exacerbations of COPD: Analysis by Diary Cards Chest, January 1, 2008; 133(1): 34 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Wedzicha, P. M. A. Calverley, T. A. Seemungal, G. Hagan, Z. Ansari, R. A. Stockley, and for the INSPIRE Investigators The Prevention of Chronic Obstructive Pulmonary Disease Exacerbations by Salmeterol/Fluticasone Propionate or Tiotropium Bromide Am. J. Respir. Crit. Care Med., January 1, 2008; 177(1): 19 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. Camp and S. M. Goring Gender and the Diagnosis, Management, and Surveillance of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, December 1, 2007; 4(8): 686 - 691. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Qaseem, V. Snow, P. Shekelle, K. Sherif, T. J. Wilt, S. Weinberger, D. K. Owens, and for the Clinical Efficacy Assessment Subcommittee Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline from the American College of Physicians Ann Intern Med, November 6, 2007; 147(9): 633 - 638. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Wilt, D. Niewoehner, R. MacDonald, and R. L. Kane Management of Stable Chronic Obstructive Pulmonary Disease: A Systematic Review for a Clinical Practice Guideline Ann Intern Med, November 6, 2007; 147(9): 639 - 653. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kesten, M. Plautz, C. A. Piquette, M. P. Habib, and D. E. Niewoehner Premature discontinuation of patients: a potential bias in COPD clinical trials Eur. Respir. J., November 1, 2007; 30(5): 898 - 906. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. A. Hanania and J. F. Donohue Pharmacologic Interventions in Chronic Obstructive Pulmonary Disease: Bronchodilators Proceedings of the ATS, October 1, 2007; 4(7): 526 - 534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. F. Rabe, S. Hurd, A. Anzueto, P. J. Barnes, S. A. Buist, P. Calverley, Y. Fukuchi, C. Jenkins, R. Rodriguez-Roisin, C. van Weel, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary Am. J. Respir. Crit. Care Med., September 15, 2007; 176(6): 532 - 555. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Powrie, T. M. A. Wilkinson, G. C. Donaldson, P. Jones, K. Scrine, K. Viel, S. Kesten, and J. A. Wedzicha Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD Eur. Respir. J., September 1, 2007; 30(3): 472 - 478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Baughman, B. K. Sparkman, and E. E. Lower Six-Minute Walk Test and Health Status Assessment in Sarcoidosis Chest, July 1, 2007; 132(1): 207 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. R. Celli and P. J. Barnes Exacerbations of chronic obstructive pulmonary disease Eur. Respir. J., June 1, 2007; 29(6): 1224 - 1238. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Oba Cost-Effectiveness of Long-Acting Bronchodilators for Chronic Obstructive Pulmonary Disease Mayo Clin. Proc., May 1, 2007; 82(5): 575 - 582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Criner Optimal Treatment of Chronic Obstructive Pulmonary Disease: The Search for the Magic Combination of Inhaled Bronchodilators and Corticosteroids Ann Intern Med, April 17, 2007; 146(8): 606 - 608. [Full Text] [PDF]
|
|
|
|
|
|
S. D. Aaron, K. L. Vandemheen, D. Fergusson, F. Maltais, J. Bourbeau, R. Goldstein, M. Balter, D. O'Donnell, A. McIvor, S. Sharma, et al. Tiotropium in Combination with Placebo, Salmeterol, or Fluticasone Salmeterol for Treatment of Chronic Obstructive Pulmonary Disease: A Randomized Trial Ann Intern Med, April 17, 2007; 146(8): 545 - 555. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Brusasco Reducing cholinergic constriction: the major reversible mechanism in COPD Eur. Respir. Rev., December 1, 2006; 15(99): 32 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Rodriguez-Roisin Impacting patient-centred outcomes in COPD: exacerbations and hospitalisations Eur. Respir. Rev., December 1, 2006; 15(99): 47 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Decramer Tiotropium as essential maintenance therapy in COPD Eur. Respir. Rev., December 1, 2006; 15(99): 51 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kesten, M. Jara, C. Wentworth, and S. Lanes Pooled Clinical Trial Analysis of Tiotropium Safety Chest, December 1, 2006; 130(6): 1695 - 1703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Matthiesen, A. Bahulayan, S. Kempkens, S. Haag, M. Fuhrmann, C. Stichnote, U. R. Juergens, and K. Racke Muscarinic Receptors Mediate Stimulation of Human Lung Fibroblast Proliferation Am. J. Respir. Cell Mol. Biol., December 1, 2006; 35(6): 621 - 627. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Heffner Update in pulmonary medicine. Ann Intern Med, November 21, 2006; 145(10): 765 - 773. [Full Text] [PDF]
|
|
|
|
|
|
P. P. Walker, P. Mitchell, F. Diamantea, C. J. Warburton, and L. Davies Effect of primary-care spirometry on the diagnosis and management of COPD Eur. Respir. J., November 1, 2006; 28(5): 945 - 952. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R G Barr, J Bourbeau, C A Camargo, and F S F Ram Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis Thorax, October 1, 2006; 61(10): 854 - 862. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. O. D'Souza, M. J. Smith, L. A. Miller, and J. Kavookjian An Appraisal of Pharmacoeconomic Evidence of Maintenance Therapy for COPD Chest, June 1, 2006; 129(6): 1693 - 1708. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Mahler Mechanisms and Measurement of Dyspnea in Chronic Obstructive Pulmonary Disease Proceedings of the ATS, May 1, 2006; 3(3): 234 - 238. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Vestbo Clinical Assessment, Staging, and Epidemiology of Chronic Obstructive Pulmonary Disease Exacerbations Proceedings of the ATS, May 1, 2006; 3(3): 252 - 256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Burge Prevention of Exacerbations: How Are We Doing and Can We Do Better? Proceedings of the ATS, May 1, 2006; 3(3): 257 - 261. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. F. Rabe Improving Dyspnea in Chronic Obstructive Pulmonary Disease: Optimal Treatment Strategies Proceedings of the ATS, May 1, 2006; 3(3): 270 - 275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Scott, P Walker, and P M A Calverley COPD exacerbations {middle dot} 4: Prevention Thorax, May 1, 2006; 61(5): 440 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W. Jones and A. G. N. Agusti Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur. Respir. J., April 1, 2006; 27(4): 822 - 832. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D E O'Donnell and C M Parker COPD exacerbations {middle dot} 3: Pathophysiology. Thorax, April 1, 2006; 61(4): 354 - 361. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Dusser, M-L. Bravo, P. Iacono, and on behalf the MISTRAL study group The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur. Respir. J., March 1, 2006; 27(3): 547 - 555. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. van Noord, J. L. Aumann, E. Janssens, J. Verhaert, J. J. Smeets, A. Mueller, and P. J. G. Cornelissen Effects of Tiotropium With and Without Formoterol on Airflow Obstruction and Resting Hyperinflation in Patients With COPD Chest, March 1, 2006; 129(3): 509 - 517. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. I. Rennard, N. Schachter, M. Strek, K. Rickard, and O. Amit Cilomilast for COPD: Results of a 6-Month, Placebo-Controlled Study of a Potent, Selective Inhibitor of Phosphodiesterase 4 Chest, January 1, 2006; 129(1): 56 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. R. Celli Chronic Obstructive Pulmonary Disease: From Unjustified Nihilism to Evidence-based Optimism. Proceedings of the ATS, January 1, 2006; 3(1): 58 - 65. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V Brusasco, R Hodder, M Miravitlles, L Korducki, L Towse, and S Kesten Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD Thorax, January 1, 2006; 58(5): 399 - 404. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Soler Modulation of airway inflammation to prevent exacerbations of COPD Eur. Respir. Rev., December 1, 2005; 14(95): 78 - 82. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. E. Belmonte Cholinergic Pathways in the Lungs and Anticholinergic Therapy for Chronic Obstructive Pulmonary Disease Proceedings of the ATS, November 1, 2005; 2(4): 297 - 304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Niewoehner, K. Rice, C. Cote, D. Paulson, J. A. D. Cooper Jr., L. Korducki, C. Cassino, and S. Kesten Prevention of Exacerbations of Chronic Obstructive Pulmonary Disease with Tiotropium, a Once-Daily Inhaled Anticholinergic Bronchodilator: A Randomized Trial Ann Intern Med, September 6, 2005; 143(5): 317 - 326. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Turino Therapeutic Gains of Prolonged Bronchial Dilatation in Chronic Obstructive Pulmonary Disease Ann Intern Med, September 6, 2005; 143(5): 386 - 387. [Full Text] [PDF]
|
|
|
|
|
|
P. Calverley, R. Pauwels{dagger}, C-G. Lofdahl, K. Svensson, T. Higenbottam, L-G. Carlsson, and E. Stahl Relationship between respiratory symptoms and medical treatment in exacerbations of COPD Eur. Respir. J., September 1, 2005; 26(3): 406 - 413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Barnes New approaches to COPD Eur. Respir. Rev., September 1, 2005; 14(94): 2 - 11. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Vincken Bronchodilator treatment of stable COPD: long-acting anticholinergics Eur. Respir. Rev., September 1, 2005; 14(94): 23 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Maltais, A. Hamilton, D. Marciniuk, P. Hernandez, F. C. Sciurba, K. Richter, S. Kesten, and D. O'Donnell Improvements in Symptom-Limited Exercise Performance Over 8 h With Once-Daily Tiotropium in Patients With COPD Chest, September 1, 2005; 128(3): 1168 - 1178. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Somand and T. L Remington Tiotropium: A Bronchodilator for Chronic Obstructive Pulmonary Disease Ann. Pharmacother., September 1, 2005; 39(9): 1467 - 1475. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. A. Calverley Long-acting inhaled bronchodilators in COPD: how many drugs do we need? Eur. Respir. J., August 1, 2005; 26(2): 190 - 191. [Full Text] [PDF]
|
|
|
|
|
|
J. A. van Noord, J-L. Aumann, E. Janssens, J. J. Smeets, J. Verhaert, B. Disse, A. Mueller, and P. J. G. Cornelissen Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD Eur. Respir. J., August 1, 2005; 26(2): 214 - 222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J J Swigris, W G Kuschner, S S Jacobs, S R Wilson, and M K Gould Health-related quality of life in patients with idiopathic pulmonary fibrosis: a systematic review Thorax, July 1, 2005; 60(7): 588 - 594. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Troosters, R. Casaburi, R. Gosselink, and M. Decramer Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., July 1, 2005; 172(1): 19 - 38. [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Olin Tiotropium: An inhaled anticholinergic for chronic obstructive pulmonary disease Am. J. Health Syst. Pharm., June 15, 2005; 62(12): 1263 - 1269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Barnes and R. A. Stockley COPD: current therapeutic interventions and future approaches Eur. Respir. J., June 1, 2005; 25(6): 1084 - 1106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Buhl and S. G. Farmer Future Directions in the Pharmacologic Therapy of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, April 1, 2005; 2(1): 83 - 93. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Vestbo, R Pauwels, J A Anderson, P Jones, P Calverley, and on behalf of the TRISTAN study group Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease Thorax, April 1, 2005; 60(4): 301 - 304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Decramer, R Gosselink, M Rutten-Van Molken, J Buffels, O Van Schayck, P-A Gevenois, R Pellegrino, E Derom, and W De Backer Assessment of progression of COPD: report of a workshop held in Leuven, 11-12 March 2004 Thorax, April 1, 2005; 60(4): 335 - 342. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Decramer, R Gosselink, P Bartsch, C-G Lofdahl, W Vincken, R Dekhuijzen, J Vestbo, R Pauwels, R Naeije, and T Troosters Effect of treatments on the progression of COPD: report of a workshop held in Leuven, 11-12 March 2004 Thorax, April 1, 2005; 60(4): 343 - 349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Casaburi, D. Kukafka, C. B. Cooper, T. J. Witek Jr, and S. Kesten Improvement in Exercise Tolerance With the Combination of Tiotropium and Pulmonary Rehabilitation in Patients With COPD Chest, March 1, 2005; 127(3): 809 - 817. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Barnes Distribution of Receptor Targets in the Lung Proceedings of the ATS, December 1, 2004; 1(4): 345 - 351. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Gross Tiotropium Bromide Chest, December 1, 2004; 126(6): 1946 - 1953. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Mahler, S. Huang, M. Tabrizi, and G. M. Bell Efficacy and Safety of a Monoclonal Antibody Recognizing Interleukin-8 in COPD: A Pilot Study Chest, September 1, 2004; 126(3): 926 - 934. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J R Hurst and J A Wedzicha Chronic obstructive pulmonary disease: the clinical management of an acute exacerbation Postgrad. Med. J., September 1, 2004; 80(947): 497 - 505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.E. O'Donnell, T. Fluge, F. Gerken, A. Hamilton, K. Webb, B. Aguilaniu, B. Make, and H. Magnussen Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD Eur. Respir. J., June 1, 2004; 23(6): 832 - 840. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B.R. Celli, W. MacNee, A. Agusti, A. Anzueto, B. Berg, A.S. Buist, P.M.A. Calverley, N. Chavannes, T. Dillard, B. Fahy, et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper Eur. Respir. J., June 1, 2004; 23(6): 932 - 946. [Full Text] [PDF]
|
|
|
|
|
|
A. Hasani, N. Toms, J. E. Agnew, M. Sarno, A. J. Harrison, and P. Dilworth The Effect of Inhaled Tiotropium Bromide on Lung Mucociliary Clearance in Patients With COPD Chest, May 1, 2004; 125(5): 1726 - 1734. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Miravitlles, M Ferrer, A Pont, R Zalacain, J L Alvarez-Sala, F Masa, H Verea, C Murio, F Ros, and R Vidal Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study Thorax, May 1, 2004; 59(5): 387 - 395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J A Wedzicha Short burst oxygen therapy is helpful? Chronic Respiratory Disease, April 1, 2004; 1(2): 101 - 103. [PDF]
|
|
|
|
|
|
R. A. Pauwels Similarities and Differences in Asthma and Chronic Obstructive Pulmonary Disease Exacerbations Proceedings of the ATS, April 1, 2004; 1(2): 73 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. A. Calverley Reducing the Frequency and Severity of Exacerbations of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, April 1, 2004; 1(2): 121 - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. G. Barr Management of Chronic Obstructive Pulmonary Disease JAMA, March 3, 2004; 291(9): 1066 - 1067. [Full Text] [PDF]
|
|
|
|
|
|
J.B. Oostenbrink, M.P.M.H. Rutten-van Molken, M.J. Al, J.A. Van Noord, and W. Vincken One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease Eur. Respir. J., February 1, 2004; 23(2): 241 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Turck, W. Weber, R. Sigmund, K. Budde, H.-H. Neumayer, L. Fritsche, K.-L. Rominger, U. Feifel, and T. Slowinski Pharmacokinetics of Intravenous, Single-Dose Tiotropium in Subjects with Different Degrees of Renal Impairment J. Clin. Pharmacol., February 1, 2004; 44(2): 163 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cazzola and M. G. Matera Long-Acting Bronchodilators Are the First-Choice Option for the Treatment of Stable COPD Chest, January 1, 2004; 125(1): 9 - 11. [Full Text] [PDF]
|
|
|
|
|
|
D. P. Tashkin and C. B. Cooper The Role of Long-Acting Bronchodilators in the Management of Stable COPD Chest, January 1, 2004; 125(1): 249 - 259. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G.C. Donaldson, T.A.R. Seemungal, I.S. Patel, S.J. Lloyd-Owen, T.M.A. Wilkinson, and J.A. Wedzicha Longitudinal changes in the nature, severity and frequency of COPD exacerbations Eur. Respir. J., December 1, 2003; 22(6): 931 - 936. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. K. Leidy, S. I. Rennard, J. Schmier, M. K. C. Jones, and M. Goldman The Breathlessness, Cough, and Sputum Scale: The Development of Empirically Based Guidelines for Interpretation Chest, December 1, 2003; 124(6): 2182 - 2191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. R. Celli A 62-Year-Old Woman With Chronic Obstructive Pulmonary Disease JAMA, November 26, 2003; 290(20): 2721 - 2729. [Full Text] [PDF]
|
|
|
|
|
|
M. Decramer Treatment of chronic respiratory failure: lung volume reduction surgery versus rehabilitation Eur. Respir. J., November 16, 2003; 22(47_suppl): 47s - 56s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. D. Sin, F. A. McAlister, S. F. P. Man, and N. R. Anthonisen Contemporary Management of Chronic Obstructive Pulmonary Disease: Scientific Review JAMA, November 5, 2003; 290(17): 2301 - 2312. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Celli, R. ZuWallack, S. Wang, and S. Kesten Improvement in Resting Inspiratory Capacity and Hyperinflation With Tiotropium in COPD Patients With Increased Static Lung Volumes Chest, November 1, 2003; 124(5): 1743 - 1748. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P J Barnes Chronic obstructive pulmonary disease * 12: New treatments for COPD Thorax, September 1, 2003; 58(9): 803 - 808. [Full Text] [PDF]
|
|
|
|
|
|
S.I. Rennard and P. Calverley Rescue! Therapy and the paradox of the Barcalounger Eur. Respir. J., June 1, 2003; 21(6): 916 - 917. [Full Text] [PDF]
|
|
|
|
|
|
S. Burge and J.A. Wedzicha COPD exacerbations: definitions and classifications Eur. Respir. J., June 1, 2003; 21(41_suppl): 46S - 53s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Tashkin and S. Kesten Long-term Treatment Benefits With Tiotropium in COPD Patients With and Without Short-term Bronchodilator Responses Chest, May 1, 2003; 123(5): 1441 - 1449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M R Partridge Patients with COPD: do we fail them from beginning to end? Thorax, May 1, 2003; 58(5): 373 - 375. [Full Text]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |